Sharma, AshishMadhusudhan, Rangasamy JNadahalli, VidhyaDamgude, Shreekant ASundaramoorthy, Selva K2012-07-122012-07-122012-05Sharma Ashish, Madhusudhan Rangasamy J, Nadahalli Vidhya, Damgude Shreekant A, Sundaramoorthy Selva K. Change in macular thickness in a case of refractory diabetic macular edema with dexamethasone intravitreal implant in comparison to intravitreal bevacizumab: A case report. Indian Journal of Ophthalmology. 2012 May; 60(3): 234-235.http://imsear.searo.who.int/handle/123456789/139482We report on the significant improvement of central macular thickness in a case of clinically significant macular edema after dexamethasone 0.7 mg sustained-release intravitreal implant (Ozurdex®; Allergan, Inc, Irvine, CA, USA). Patient presented to us with persistent clinically significant macular edema (CSME) in both eyes. Right eye received dexamethasone implant and left eye received two intravitreal bevacizumab injections 1.25 mg/0.05 mL (Avastin®; Genentech Inc., South San Francisco, CA, USA) with an interval of four weeks. After six weeks of follow-up, dexamethasone implant in the right eye showed normal macular thickness whereas persistent macular edema (ME) was found even after second intravitreal bevacizumab injection in the left eye.enClinically significant macular edemadexamethasoneimplantozurdexAdultAngiogenesis Inhibitors --administration & dosageAntibodies, Monoclonal, Humanized --administration & dosageDexamethasone --administration & dosageDiabetic Retinopathy --complicationsDiabetic Retinopathy --drug therapyDisease ProgressionDrug ImplantsFollow-Up StudiesGlucocorticoids --administration & dosageHumansIntravitreal InjectionsMacula Lutea --drug effectsMacula Lutea --pathologyMacular Edema --drug therapyMaleTomography, Optical CoherenceVascular Endothelial Growth Factor A --antagonists & inhibitorsVisual AcuityArticle